Hospital Privado de Rosario.
Unidad de Tiroides y Paratiroides del Grupo Gamma .
Rev Fac Cien Med Univ Nac Cordoba. 2022 Dec 21;79(4):353-357. doi: 10.31053/1853.0605.v79.n4.35157.
Levothyroxine (LT4) has been considered the standard of care for treatment of hypothyroidism. Current recommendations suggest a LT4 dose between 1.6-1.8 µg/kg/day. The aim of this study was to evaluate the LT4 dose for adult patients with primary hypothyroidism of different etiologies who reached euthyroidism.
A cross-sectional study was performed from the retrospective review of the charts of patients with primary hypothyroidism in treatment with LT4. Subjects were classified according to TSH level in overtreated (TSH < 0.4 µIU/ml), euthyroid (TSH 0.40-4.20), and undertreated (TSH >4.2) and according to the etiology of hypothyroidism. A stepwise logistic regression model was performed to evaluate the variables associated with TSH<0.4 µIU/ml.
955 patients were included. 75.13% of the patients had an adequate LT4 replacement. LT4 dose to achieve euthyroidism was higher in patients with a history of radioiodine therapy (1.92 μg/kg) and thyroid surgery (1.52 μg/kg), while the LT4 dose required to achieve euthyroidism in patients with Hashimoto's thyroiditis and atrophic thyroiditis was lower than that reported in previous studies (1.25 and 1.08 μg/kg, respectively). The variables that were associated with a higher probability of TSH<0.4 µIU/ml were male gender, Hashimoto's thyroiditis, radioiodine therapy, and thyroid surgery.
LT4 dose required to achieve euthyroidism in patients with hypothyroidism varies according to the etiology, being higher in patients with hypothyroidism due to radioiodine therapy and thyroid surgery. Patients with hypothyroidism due to Hashimoto's thyroiditis and atrophic thyroiditis require a lower dose than current recommendations.
左甲状腺素(LT4)一直被认为是治疗甲状腺功能减退症的标准治疗方法。目前的建议建议 LT4 剂量在 1.6-1.8μg/kg/天之间。本研究的目的是评估不同病因的原发性甲状腺功能减退症达到甲状腺功能正常的成年患者的 LT4 剂量。
对接受 LT4 治疗的原发性甲状腺功能减退症患者的病历进行回顾性横断面研究。根据 TSH 水平将受试者分为治疗过度组(TSH<0.4μIU/ml)、甲状腺功能正常组(TSH 0.40-4.20)和治疗不足组(TSH>4.2),并根据甲状腺功能减退症的病因进行分类。采用逐步逻辑回归模型评估与 TSH<0.4μIU/ml 相关的变量。
共纳入 955 例患者。75.13%的患者 LT4 替代治疗充足。有放射性碘治疗史(1.92μg/kg)和甲状腺手术史(1.52μg/kg)的患者达到甲状腺功能正常所需的 LT4 剂量较高,而桥本甲状腺炎和萎缩性甲状腺炎患者达到甲状腺功能正常所需的 LT4 剂量低于既往研究报道的剂量(分别为 1.25μg/kg 和 1.08μg/kg)。与 TSH<0.4μIU/ml 发生概率较高相关的变量为男性、桥本甲状腺炎、放射性碘治疗和甲状腺手术。
甲状腺功能减退症患者达到甲状腺功能正常所需的 LT4 剂量因病因而异,放射性碘治疗和甲状腺手术所致甲状腺功能减退症患者的剂量较高。桥本甲状腺炎和萎缩性甲状腺炎所致甲状腺功能减退症患者需要的剂量低于目前的建议。